Marijuana Is Associated With a Hormonal Imbalance Among Several Habits Related to Male Infertility: A Retrospective Study

Marijuana is one of the most consumed drugs worldwide. There is increasing evidence of an association between marijuana and male infertility. This study intends to assess the repercussion of marijuana smoking and other habits (sedentary lifestyle, alcohol, and tobacco use) in the testicular function of infertile men seeking andrological evaluation. A retrospective study was performed using medical records data of men aged 18–59 years from 2009 to 2017. Complete semen analyses, sperm functional tests, SHBG, and hormonal levels, testosterone-to-estradiol ratio (T/E₂), and testis volume were evaluated. Exclusion criteria included cryptorchidism, infertility caused by genetic or infectious diseases, and cancer. A multiple linear regression analysis was performed to investigate which habit could predict certain parameters using the software SPSS 23.0 (P < 0.05). In a sample of 153 men, semen parameters, testosterone levels, and testis volume were not significantly influenced. Marijuana use had the broader hormonal changes since it influences estradiol (P = 0.000; B = −11.616), prolactin (P = 0.000; B = 3.211), SHBG levels (P = 0.017; B = 7.489), and T/E₂ (P = 0.004; B = 14.030). Sedentary lifestyle (P = 0.028; B = 1.279) and tobacco smoking (P = 0.031; B = −2.401) influenced the prolactin levels. Marijuana is associated with hormonal imbalance in this infertile cohort by lowering estradiol levels and inhibiting aromatase function.

Introduction

Produced on every continent, marijuana (cannabis made from the dried flowers and leaves of the plant Cannabis sativa) is one of the most widely consumed drugs with ~188 million users or 3.8% of the world's population between 15 and 64 years of age (1). Although marijuana is illegal in most countries, its use is currently rising worldwide, mainly for recreational use and recently for alleged and realistic medical purposes, particularly among men of childbearing age (2).

Infertility is a disease described as the inability to conceive after 12 months of regular sexual intercourse without using a contraceptive method (3). The male reproductive function has been the subject of particular attention in recent years due to the accumulation of data on a possible deterioration in sperm counts and quality related to various environmental and behavioral factors (4). In recent decades, numerous investigations have raised the impacts of lifestyle and environment on male fertility (5). Among the wide range of environmental factors that can affect men's fertility, some evidence suggests an association between chronic marijuana use and male infertility (6).

Overall, most human studies associate marijuana use with a deleterious impact on male fertility status, mainly because of the correlation with lower sperm concentrations, morphologic abnormalities, and reduced motility and viability (6–9). Nonetheless, current evidence seems conflicting regarding the effects of cannabis on male reproductive endocrine function, with an emphasis on the inconclusive findings in testosterone levels, concomitant with reduced luteinizing hormone (LH) and unchanged follicle-stimulating hormone (FSH) concentrations (7–12).

The study reported here aims to evaluate the effects of marijuana, within other conditions (obesity, sedentary lifestyle, smoking, alcohol consumption), on the spermatozoa function and sex hormone levels in reproductive failure situations in patients attending an andrology setting.

Materials and Methods

Study Design and Patients

This cross-sectional study was carried out using data from the medical records of 316 infertile men aged 18–60 years who attended a referral center for male sexual and reproductive health in São Paulo, Brazil (Androscience, Science & Innovation Center, High Complex Clinical & Research Andrology Laboratory) between 2009 and 2017. All men presented two complete seminal analyses (13) and were assessed for total serum testosterone concentration collected in the initial clinical assessment (maximum interval of 15 days). The assessment also included a mandatory measurement of testicular volume (TV) using an ultrasound with calculated TV deduced from the ellipsoidal formula:

$\begin{array}{l}\text{TV }(\text{c}{\text{m}}^3)=\left[\text{length }(\text{cm})\text{ X width }(\text{cm})\text{ X depth }(\text{cm})\text{ X }0.52\right]\end{array}$

Exclusion criteria included cryptorchidism, or other severe testicular dysfunction (atrophy, testicular dysgenesis syndrome), genetic infertility (Y-chromosome micro-deletions, karyotype abnormalities), clinical infection of the urogenital tract, previous cancer treatments (radiation or chemotherapy), previous scrotal surgeries, and use of anabolic steroids or testosterone replacement therapy. As a result, of the 316 patients, the final sample size was reduced to 153 men (Figure 1). Varicocele, which accounted for a large proportion of cases, was not considered as an exclusion criterium. It was assessed and classified accordingly to Dubin and Amelar's criteria (14). It was included in the regression model to control its influence, as was the case with patients clinically classified as obese.

FIGURE 1

Figure 1. Patient selection diagram.

Our assessment also included the patient's information regarding obesity status, sedentary lifestyle, the extent of smoking, alcohol, and marijuana use. The obesity status was assessed using the body mass index (BMI), and two sub-groups of patients were defined. Patients with a BMI <30 have been considered “non-obese,” while patients with a BMI >30 have been considered obese (15). The extent of tobacco smoking was categorized as less than ten pack-years (moderate smoker), equivalent or more than ten pack-years (heavy smoker). “Pack-years” classically corresponds to a person smoking one pack of cigarettes per day for less or more than 10 years (16). The daily consumption of alcoholic beverages was divided into two groups (< three doses/day and ≥ three doses/day), according to WHO standards of presumed damage, in which one dose corresponds to 40 ml of whisky or a 140 ml glass of wine or a 330 ml can of beer (17). Marijuana smoking was defined as drug use at least once a week for a minimum of 12 months (18).

The study was conducted according to the guidelines of the Declaration of Helsinki (19), and approved by the Institutional Review Board (or Ethics Committee) of the Faculty of Medicine of the University of São Paulo, Brazil (registration number: CAAE 92728018.0.0000.0068). The Institutional Ethics Committee exempted using an informed consent form because all data were collected from medical records, and there was no clinical intervention.

Seminal and Hormonal Analysis

All semen analyses were performed in Androscience, Science and Innovation Center, High-Complex Clinical and Research Andrology Laboratory. Samples were obtained by masturbation after sexual abstinence for 2–5 days. Semen analysis was performed according to WHO guidelines (13). It included the following parameters: pH, volume (ml), concentration (×10⁶/ml), progressive motility (%) and total motility (%), total sperm count (×10⁶), total motile sperm count (×10⁶), total sperm with progressive motility (×10⁶). Sperm morphological analysis was performed using the strict criteria (20). For the statistical model, the mean value for each semen parameter was calculated using the values from the two baseline semen analysis, assuring that no intervention was performed between these two semen collections.

Data from biochemical markers of sperm function and sperm function assays were also collected. Briefly, anti-sperm antibodies were evaluated using the commercial Marscreen kit (Bioscreen New York, NY, USA). According to Huszar et al. (21), creatine kinase activity was evaluated using a Spectroquant Pharo 300 spectrophotometer (Marck, Germany). The results are expressed in units for 10⁸ spermatozoa. The levels of reactive oxygen species (ROS) were evaluated by chemiluminescence (Autolumat Plus luminometer, Bertold Technologies, Germany), and the results were expressed in 10⁴ photons/minute (cpm) for 20 × 10⁶ spermatozoa. The assessment of sperm DNA integrity was performed by the SCSA^® (Sperm Chromatin Structure Assay) method, and data were analyzed to determine the DNA Fragmentation Index (DFI%).

Levels of LH (in μU/l), FSH (in μU/l), total testosterone (TT, in ng/dl), prolactin (PRL, in ng/ml), estradiol (E2, in pg/ml), and sex hormone-binding globulin (SHBG, in nmol/l) were measured by an electrochemiluminescent immunoassay kit (ECLIA kit; Roche Diagnostics, Mannheim, Germany). Hormones and SHBG measurements were extracted from a specific database and performed in the same laboratory following the morning sampling recommendation.

Statistical Analysis

Patients were characterized by age, obesity, the presence of clinical varicocele (14), personal information about tobacco and cannabis use, alcohol consumption, and sedentary lifestyle. Semen parameters, hormonal levels (LH, FSH, total testosterone, prolactin, estradiol), SHBG content, and testosterone/estradiol ratio (T/E2) were recorded and evaluated as variables. The categorical data were described by absolute number, frequency, and proportion. Constantly changing data were described by the mean and standard deviation (SD). The data were subjected to the Shapiro-Wilk test to confirm the distribution of normality (P < 0.01). Multiple linear regression analysis was performed to determine which habit or lifestyle factors (tobacco use, daily alcohol consumption, marijuana use, and sedentary lifestyle) could influence specific sperm parameters or hormone levels. During the analysis, age (≥45 years) and clinical varicocele were included as predictors. The ANOVA test was used to verify the association between semen or hormonal parameters and other clinical or epidemiological characteristics. All statistical analyses were performed using SPSS 23.0 (IBM Corp, Armonk, NY, USA) with a significance level of P < 0.05.

Results

Table 1 presents all the characteristics of the cohort being evaluated (n = 153 infertile males). Note the following: mean age of 38.05 ± 8.81 years (IC: 37.01–39.08); about half of the cohort was overweight, and 27 patients (17.65%) were classified as obese; 95 subjects presented a clinical varicocele, which represents a high proportion (62.09%) of the cohort but is typical of the infertile cases encountered in a referral male infertility center. Mean testicular volume was around 16 ml on both sides.

TABLE 1

Table 1. Baseline clinical and laboratorial characteristics of infertile patients (n = 153), 2009–2017.

Data represent the mean basic semen parameters of the infertile population in the study (i.e., semen volume, sperm count, sperm concentrations, percentage of progressive motility, percentage of normal morphology) were on average, i.e., above the 5% minimum percentile considered acceptable, according to WHO 2010 recommendations (7). Table 2 illustrates the seminal alterations observed in the infertile cohort analyzed according to WHO (2010) recommendations (13). Regarding lifestyle factors, tobacco smoking affected <10% of the cohort, and almost half of the patients were classified as having a sedentary lifestyle (48.37%, n = 74). Heavy to moderate alcohol consumption affected about one-third of patients (35.94%; n = 55). Finally, marijuana use concerned 27.45% of patients (n = 42). It is essential to mention that none of the cannabis smokers use other commonly associated (non-prescribed) drugs, except for two out of 42 patients, who were tobacco and marijuana smokers.

TABLE 2

Table 2. Basic semen abnormalities found in the infertile cohort (n = 153), 2009–2017.

After testing the linearity assumptions, normal distribution, and non-correlation errors, multiple linear regression analyses demonstrated that only serum estradiol (p < 0.01) and prolactin concentrations (p < 0.01), SHBG content (p = 0.01), T/E2 ratio (p = 0.01), and to a lesser extent, semen volume (p = 0.02) appeared to be influenced by the lifestyle parameters (Table 3). None of the other basic seminal parameters, sperm functional tests, and other serum hormones examined were significantly affected (Table 3). It is worth noting the elevated means for all sperm functional tests, mainly the DNA fragmentation index (42.21 ± 21.89 %) and the ROS levels (7.20 ± 19.53 × 10⁴ cpm/20 × 10⁶), far beyond the considered “normal” values (22, 23).

TABLE 3

Table 3. Summary of the multiple linear regression analysis model with constant predictors^* for hormonal/seminal parameters and testicular volume.

The beta and B regression coefficients (standardized and unstandardized coefficients, respectively), determined by the multiple linear regression analysis, were used to rank the predictors that had the most significant effect on the outcome variable (Tables 4–8). Among the distinct lifestyle predictors analyzed (obesity, physical inactivity, smoking, alcohol use, marijuana use), marijuana use revealed to provoke the most substantial effect on serum estradiol (Table 4: ß = −0.35, p < 0.01) and prolactin levels (Table 5: ß = 0.30; p < 0.01). Interestingly, marijuana use was inversely correlated with serum estradiol while positively correlated with serum prolactin. Moreover, serum prolactin levels were also negatively influenced by smoking and obesity, whereas they were positively influenced by a sedentary lifestyle (Table 5). Confirming in part the above observation, and in the absence of any observed effect on serum testosterone levels, marijuana use was also responsible for the most potent positive effect on the T/E2 ratio (Table 6: ß = 0.24; p < 0.01). Regarding the variable “SHBG content,” marijuana use also had the most influential effect (Table 7: ß = 0.19; p = 0.02). Finally, while it appeared in the Table 3 that semen volume could be correlated with the constant predictors evaluated, the Table 8 demonstrates that this parameter is not significantly influenced by marijuana use (ß = −0.03; p = 0.67). Unsurprisingly, age significantly influenced each of the dependent variables analyzed, except for the T/E₂ ratio (Table 6: ß = 0.1; p = 0.2).

TABLE 4

Table 4. Coefficients of the multiple linear regression analysis model for dependent variable Estradiol.

TABLE 5

Table 5. Coefficients of the multiple linear regression analysis model for dependent variable Prolactin.

TABLE 6

Table 6. Coefficients of the multiple linear regression analysis model for dependent variable T/E₂.

TABLE 7

Table 7. Coefficients of the multiple linear regression analysis model for dependent variable SHBG.

TABLE 8

Table 8. Coefficients of the multiple linear regression analysis model for dependent variable Semen volume.

Discussion

The disturbing worldwide progressive decrease in semen quality over the last 40-years has multifactorial interconnected origins, including environmental, toxicological, behavioral, and lifestyle-related issues. Nevertheless, the continuous search for new clues or potential agents and close interactions among human and environmental factors has been considered an urgent task by government, institutions, and scientists (24). Our study demonstrates one previously unrevealed aspect of marijuana (Cannabis sativa) consumption with deleterious effects on a specific male cohort seeking fertility evaluation in a specialized andrology setting. It is widely accepted that marijuana cannabinoids compete with endo-cannabinoids to occupy cannabinoid receptors (CB1 and CB2) along the hypothalamus-pituitary-testicular axis (25). To this day, a large body of data emphasizes the role of cannabinoids in controlling reproduction by modifying gonadotropin release, fertility, and sexual behavior (26).

Our data bring forward a significant correlation between marijuana use and lower serum estradiol (E₂) levels. The correlation also confirms a point between marijuana use and higher T/E2 ratios in the absence of any observed effect on testosterone levels. To date, conflicting data exist. While two studies based on the use of cellular models have reported that Δ9-tetrahydrocannabinol (THC), cannabinol (CBN), and cannabidiol (CBD), three major marijuana compounds, had neither pro- nor anti-estrogenic effect (27, 28), it was reported elsewhere that these same compounds might reduce E₂ levels via their effect on the sex steroid metabolizing cytochrome P450 enzymes CYP3A and CYP1B (29, 30). However, these same studies reported that marijuana smoke condensate (MSC) showed both estrogenic and anti-estrogenic effects assumed to be mediated by other marijuana compounds (27). It was proposed that phenolic compounds could be responsible for the estrogenic effect (27), while polycyclic aromatic compounds (PAHs) might account for the anti-estrogenic effect most likely via the estrogen (ER) and the aryl hydrocarbon (AhR) receptor pathways (31–34). It was also proposed that MSC could also interfere with E₂ biosynthesis via aromatase activity inhibition (28), which could agree with our observed increasing T/E₂ ratios in marijuana users. Although THC, CBD, and CBN were not linked to any aromatase inhibiting activity (28), cannabidiorcol (CBD-C1), cannabitriol (CBT), and cannabiripsol (CBR), other biologically active marijuana cannabinoids have this effect (35). A pro-estrogenic action of marijuana consumption was also suggested at the clinical and epidemiological level since it was reported to be associated with gynecomastia (36).

Several habits and lifestyle factors influenced prolactin as its serum concentration was significantly modified by marijuana use, tobacco smoking, and sedentary in infertile men. Concerning the effects of marijuana use on serum prolactin concentration, it has been suggested that the brain cannabinoid receptor (CB-1R) is expressed close to hypothalamic dopaminergic receptors and that the administration of THC provokes an increase in dopamine (DA) release (37). Through negative feedback, DA influenced prolactin secretion by the anterior pituitary (37). The interfering effect of marijuana on DA receptors could explain our data. However, the literature is still controversial, as we reported an increase in serum prolactin levels in marijuana users, whereas some other studies observed no change (7, 11, 38) while others report a decrease (39). These divergent findings will have to be further investigated. Although prolactin's physiological importance for male reproduction remains uncertain, high levels of this hormone have been associated with male infertility, probably due to a direct deleterious effect on spermatogenesis and the inhibition of pulsatile gonadotropin release (40). Concerning the influence of a sedentary lifestyle on serum prolactin levels, it was reported that physical exercise was associated with greater prolactin secretion by the anterior pituitary (41). Although the correlation we found in our study between sedentary and serum prolactin levels were not extraordinarily strong, it appears to be positive and not negative as expected. Regardless, it remains within the physiological range, which may interrogate its actual relevance.

With tobacco smoking, we recorded a weak negative influence on prolactin serum levels. The literature exhibits conflicting data with some reports identical to ours (42, 43), but others reporting increased serum prolactin levels in tobacco users (44, 45). The adverse effect proposed is that nicotine could stimulate the central dopaminergic tonus, inhibiting prolactin release by the pituitary gland (42, 43). In an experimental study using rat pituitary cell-line, nicotine inhibited the prolactin gene expression (46).

Concerning SHBG, our data suggests regular marijuana consumption was positively associated with SHBG serum levels in infertile men. BMI is considered the primary determinant of SHBG circulating levels (47), mainly via hepatic visceral fat (48). Because of that, SHBG is classically seen as a biomarker for such conditions as metabolic syndrome, type 2 diabetes, and cardiovascular diseases (49). A Danish study concerning 1,215 young men reported similar data; however, once they controlled BMI and tobacco use, serum SHBG increase was no longer significant (8). It was recently suggested that SHBG testing could help evaluate infertile men, especially in the situation of hypogonadism (50), as SHBG binds androgens and estrogens and contribute to their bioavailability (51).

In the current study, we found that marijuana did not influence serum testosterone levels in infertile men. Once again, the literature reports conflicting data with results similar to ours (10–12, 52), in other cases, a decline (7) or even an increase (8) in serum testosterone level among cannabis users. Moreover, it is worthwhile to mention that semen quality and hormonal levels could be poor biomarkers for male fertility, while time-to-pregnancy (TTP) might be more representative to couples' fertility status. In this context, a recent large retrospective study revealed that marijuana use was not associated with TTP for men and women (53).

Nevertheless, we must report some limitations of our study. As is the case for cross-sectional studies, the causal inference of many questions may remain unclear. Retrospective studies are designed to evaluate pre-existing data; therefore may be subject to a reasonable and acceptable bias. Some complimentary data such as the duration of involuntary infertility, sexual activities, female partner age are missing. Concerning the applied heterogeneous definition of “marijuana use,” it is hard to distinguish more robust user (3–5 times a day) from those light consumers because temporal and quantitative relationships were often difficult to assess, and marijuana users tend to minimize or hide their habit, considered by many as relaxing and un-harmful. Furthermore, the lack of association between semen parameters' abnormalities and any of the habits studied may be justified by the lack of a matched control group of fertile “healthy” men.

Marijuana use is associated with hormonal imbalance in a cohort of infertile men, significantly lowering E₂ serum levels while increasing prolactin serum concentrations. Further prospective studies with larger cohorts will be pertinent to corroborate our findings and improve the understanding of the underlying mechanisms that modify and regulate these perceivable endocrine changes. A warning notice should be addressed to marijuana consumers, particularly adolescents, young adults, and men in the reproductive age groups.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics Statement

The studies involving human participants were reviewed and approved by the Ethics Committee of the Faculty of Medicine of the University of São Paulo, Brazil. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author Contributions

TT, EC, and JH: conception and design of the study. II and GA: acquisition of data. TT, PS, JD, and JH: analysis and interpretation of data. TT, II, and GA: drafting the article. PS, JD, EC, and JH: revising it critically for intellectual content. All authors: final approval of the version to be submitted and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Acknowledgments

The authors wish to thank Mr. Henry Dan for their technical support; the Androscience, Science and Innovation Center in Andrology and High-Complex Clinical and Andrology Laboratory, for providing laboratorial support; and the Androscience Institute for technical support.

References

1. UNODC. World Drug Report: United Nations (2019).

Google Scholar

2. Hasin DS. US epidemiology of cannabis use and associated problems. Neuropsychopharmacol. (2018) 43:195–212. doi: 10.1038/npp.2017.198

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The international glossary on infertility and fertility care, 2017 Fertil Steril. (2017) 108:393–406. doi: 10.1016/j.fertnstert.2017.06.005

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Giwercman A, Bonde JP. Declining male fertility and environmental factors. Endocrinol Metab Clin North Am. (1998) 27:807–30. doi: 10.1016/S0889-8529(05)70042-6

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Alvarez S. Do some addictions interfere with fertility?Fertil Steril. (2015) 103:22–6. doi: 10.1016/j.fertnstert.2014.11.008

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Hsiao P, Clavijo RI. Adverse effects of cannabis on male reproduction. Eur Urol Focus. (2018) 4:324–8. doi: 10.1016/j.euf.2018.08.006

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Kolodny RC, Masters WH, Kolodner RM, Toro G. Depression of plasma testosterone levels after chronic intensive marihuana use. N Engl J Med. (1974) 290:872–4. doi: 10.1056/NEJM197404182901602

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Gundersen TD, Jorgensen N, Andersson AM, Bang AK, Nordkap L, Skakkebæk NE, et al. Association between use of marijuana and male reproductive hormones and semen quality: a study among 1,215 healthy young men. Am J Epidemiol. (2015) 182:473–81. doi: 10.1093/aje/kwv135

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Payne KS, Mazur DJ, Hotaling JM, Pastuszak AW. Cannabis and male fertility: a systematic review. J Urol. (2019) 202:674–81. doi: 10.1097/JU.0000000000000248

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Cone EJ, Johnson RE, Moore JD, Roache JD. Acute effects of smoking marijuana on hormones, subjective effects and performance in male human-subjects. Pharmacol Biochem Behav. (1986) 24:1749–54. doi: 10.1016/0091-3057(86)90515-0

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Block RI, Farinpour R, Schlechte JA. Effects of chronic marijuana use on testosterone, luteinizing-hormone, follicle-stimulating-hormone, prolactin and cortisol in men and women. Drug Alcohol Depend. (1991) 28:121–8. doi: 10.1016/0376-8716(91)90068-A

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Mendelson JH, Kuehnle J, Ellingboe J, Babor TF. Plasma testosterone levels before, during and after chronic marihuana smoking. N Engl J Med. (1974) 291:1051–5. doi: 10.1056/NEJM197411142912003

PubMed Abstract | CrossRef Full Text | Google Scholar

13. World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen. 5th Edn. Geneva: Geneva World Health Organization (2010).

Google Scholar

14. Dubin L, Amelar RF. Varicocele size and results of varicocelectomy in selected subfertile men with varicocele. Fertil Steril. (1970) 21:606–9. doi: 10.1016/S0015-0282(16)37684-1

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Obesity: preventing managing the global epidemic: report of a who consultation. World Health Organ Tech Rep Ser. (2000) 894:1–253. https://pubmed.ncbi.nlm.nih.gov/11234459/

16. Ji G, Yan L, Liu W, Qu J, Gu A. OGG1 Ser326Cys polymorphism interacts with cigarette smoking to increase oxidative DNA damage in human sperm and the risk of male infertility. Toxicol Lett. (2013) 218:144–9. doi: 10.1016/j.toxlet.2013.01.017

PubMed Abstract | CrossRef Full Text | Google Scholar

17. World Health Organization. Global Status Report on Alcohol and Health 2018.World Health Organization (2019).

Google Scholar

18. Gurney J, Shaw C, Stanley J, Signal V, Sarfati D. Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. BMC Cancer. (2015) 15:897–907. doi: 10.1186/s12885-015-1905-6

PubMed Abstract | CrossRef Full Text | Google Scholar

19. World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. (2013) 310:2191–4. doi: 10.1001/jama.2013.281053

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Kruger TF, Menkveld R, Stander FS, Lombard CJ, Van der Merwe JP, van Zyl JA, et al. Sperm morphological features as a prognostic factor in invitro fertilization. Fertil Steril. (1986) 46:1118–22. doi: 10.1016/S0015-0282(16)49891-2

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Huszar G, Vigue L, Walliman T, editors. Creatine Kinase in Sperm: The Presence of Mitochondrial and Brain-Type Creatine Kinase Isozymes. Proceedings of the Forty-First Annual Meeting of The American Fertility Society, 1985 September; Chicago. Chicago: The American Fertility Society (1985).

PubMed Abstract

22. Athayde KS, Cocuzza M, Agarwal A, Krajcir N, Lucon AM, Srougi M, et al. Development of normal reference values for seminal reactive oxygen species and their correlation with leukocytes and semen parameters in a fertile population. J Androl. (2007) 28:613–20. doi: 10.2164/jandrol.106.001966

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Evenson DP. The Sperm Chromatin Structure Assay. (SCSA^®) and other sperm DNA fragmentation tests for evaluation of sperm nuclear DNA integrity as related to fertility. Anim Reprod Sci. (2016) 169:56–75. doi: 10.1016/j.anireprosci.2016.01.017

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Skakkebaek NE, Rajpert-De Meyts E, Buck Louis GM, Toppari J, Andersson AM, Eisenberg ML, et al. Male reproductive disorders and fertility trends: influences of environment and genetic susceptibility. Physiol Rev. (2016) 96:55–97. doi: 10.1152/physrev.00017.2015

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Du Plessis SS, Agarwal A, Syriac A. Marijuana, phytocannabinoids, the endocannabinoid system, and male fertility. J Assist Reprod Genet. (2015) 32:1575–88. doi: 10.1007/s10815-015-0553-8

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. (2006) 27:73–100. doi: 10.1210/er.2005-0009

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Lee SY, Oh SM, Chung KH. Estrogenic effects of marijuana smoke condensate and cannabinoid compounds. Toxicol Appl Pharmacol. (2006) 214:270–8. doi: 10.1016/j.taap.2005.12.019

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Lee SY, Oh SM, Lee SK, Chung KH. Antiestrogenic effects of marijuana smoke condensate and cannabinoid compounds. Arch Pharm Res. (2005) 28:1365–75. doi: 10.1007/BF02977903

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Yamazaki H, Shaw PM, Guengerich FP, Shimada T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol. (1998) 11:659–65. doi: 10.1021/tx970217f

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. (2005) 227:115–24. doi: 10.1016/j.canlet.2004.10.007

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Chaloupka K, Krishnan V, Safe S. Polynuclear aromatic hydrocarbon carcinogens as antiestrogens in mcf-7 human breast-cancer cells - role of the ah receptor. Carcinogenesis. (1992) 13:2233–9. doi: 10.1093/carcin/13.12.2233

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Arcaro KF, O'Keefe PW, Yang Y, Clayton W, Gierthy JF. Antiestrogenicity of environmental polycyclic aromatic hydrocarbons in human breast cancer cells. Toxicology. (1999) 133:115–27. doi: 10.1016/S0300-483X(99)00018-9

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Tran DQ, Ide CF, mclachlan JA, Arnold SF. The anti-estrogenic activity of selected polynuclear aromatic hydrocarbons in yeast expressing human estrogen receptor. Biochem Biophys Res Commun. (1996) 229:102–8. doi: 10.1006/bbrc.1996.1764

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Safe S, Wormke M. Inhibitory aryl hydrocarbon receptor-estrogen receptor alpha cross-talk and mechanisms of action. Chem Res Toxicol. (2003) 16:807–16. doi: 10.1021/tx034036r

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Baroi S, Saha A, Bachar R, Bachar SC. Cannabinoid as potential aromatase inhibitor through molecular modeling and screening for anti-cancer activity. DUJPS. (2020) 19:47–58. doi: 10.3329/dujps.v19i1.47818

CrossRef Full Text | Google Scholar

36. Maseroli E, Rastrelli G, Corona G, Boddi V, Amato AML, Mannucci E, et al. Gynecomastia in subjects with sexual dysfunction. J Endocrinol Invest. (2014) 37:525–32. doi: 10.1007/s40618-014-0055-z

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Rodriguez De Fonseca F, Gorriti MA, Bilbao A, Escuredo L, Garcia-Segura LM, Piomelli D, et al. Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia. Neurotox Res. (2001) 3:23–35. doi: 10.1007/BF03033228

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Hallak J. Effects of Continuous Use of Marijuana and Cigarette Smoking in Testicular Function and Its Relationship With Hypogonadism and Male Infertility [thesis]. São Paulo. (SP): Univ. of São Paulo (2018).

39. Ranganathan M, Braley G, Pittman B, Cooper T, Perry E, Krystal J, et al. The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology. (2009) 203:737–44. doi: 10.1007/s00213-008-1422-2

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Dabbous Z, Atkin SL. Hyperprolactinaemia in male infertility: clinical case scenarios. Arab J Urol. (2018) 16:44–52. doi: 10.1016/j.aju.2017.10.002

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. (2013) 6:168–75. doi: 10.4103/0974-1208.121400

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Trummer H, Habermann H, Haas J, Pummer K. The impact of cigarette smoking on human semen parameters and hormones. Hum Reprod. (2002) 17:1554–9. doi: 10.1093/humrep/17.6.1554

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Andersen AN, Semczuk M, Tabor A. Prolactin and pituitary-gonadal function in cigarette-smoking infertile patients. Andrologia. (1984) 16:391–6. doi: 10.1111/j.1439-0272.1984.tb00381.x

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Xue Y, Morris M, Ni L, Guthrie SK, Zubieta JK, Gonzalez K, et al. Venous plasma nicotine correlates of hormonal effects of tobacco smoking. Pharmacol Biochem Behav. (2010) 95:209–15. doi: 10.1016/j.pbb.2010.01.007

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Blanco-Munoz J, Lacasana M, Aguilar-Garduno C. Effect of current tobacco consumption on the male reproductive hormone profile. Sci Total Environm. (2012) 426:100–5. doi: 10.1016/j.scitotenv.2012.03.071

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Coleman DT, Bancroft C. Nicotine acts directly on pituitary gh(3) cells to inhibit prolactin promoter activity. J Neuroendocrinol. (1995) 7:785–9. doi: 10.1111/j.1365-2826.1995.tb00715.x

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab. (1977) 45:1211–9. doi: 10.1210/jcem-45-6-1211

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Peter A, Kantartzis K, Machann J, Schick F, Staiger H, Machicao F, et al. Relationships of circulating sex hormone-binding globulin with metabolic traits in humans. Diabetes. (2010) 59:3167–73. doi: 10.2337/db10-0179

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Simo R, Saez-Lopez C, Barbosa-Desongles A, Hernandez C, Selva DM. Novel insights in SHBG regulation and clinical implications. Trends Endocrinol Metabol. (2015) 26:376–83. doi: 10.1016/j.tem.2015.05.001

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Ring J, Welliver C, Parenteau M, Markwell S, Brannigan RE, Köhler TS. The utility of sex hormone-binding globulin in hypogonadism and infertile males. J Urol. (2017) 197:1326–31. doi: 10.1016/j.juro.2017.01.018

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Pugeat M, Nader N, Hogeveen K, Raverot G, Dechaud H, Grenot C. Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome. Mol Cell Endocrinol. (2010) 316:53–9. doi: 10.1016/j.mce.2009.09.020

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Hart RJ, Doherty DA, McLachlan RI, Walls ML, Keelan JA, Dickinson JE, et al. Testicular function in a birth cohort of young men. Hum Reprod. (2015) 30:2713–24. doi: 10.1093/humrep/dev244

PubMed Abstract | CrossRef Full Text | Google Scholar

53. Kasman AM, Thoma ME, McLain AC, Eisenberg ML. Association between use of marijuana and time to pregnancy in men and women; findings from the National Survey of Family Growth. Fertil Steril. (2018) 109:866–71. doi: 10.1016/j.fertnstert.2018.01.015

PubMed Abstract | CrossRef Full Text | Google Scholar